6. Revenue

The Company recognized revenue under its license and collaboration agreements with SymBio, HanX and Pint as follows (See Note 14):


	Year ended December 31,
	2018		2017
Symbio
Upfront license fee recognition over time	$	398,000	$	455,000
Supplies		61,000		332,000

Hanx
Upfront license payment recognized at a point in time		450,000		—

Pint
Upfront license payment recognized at a point it time		319,000		—
	$	1,228,000	$	787,000

Deferred revenue is as follows:


	Symbio
	Upfront Payment
Deferred balance at December 31, 2017	$	4,546,000
Recognition to revenue		398,000

Deferred balance at December 31, 2018	$	4,148,000

See Note 14, “License and Collaboration Agreements,” for a further discussion of the agreements with SymBio and HanX.